Mix-n-match COVID boosters may produce more durable immunity

A single-center study today in JAMA Network Open finds longer-lasting humoral and cellular immune responses in US adults given a Johnson & Johnson (J&J) COVID-19 vaccine booster rather than a Pfizer/BioNTech booster after receiving two doses of the Pfizer vaccine at least 6 months earlier.

Researchers from Beth Israel Deaconess Medical Center led the study of 68 adults in Boston given either a Pfizer or a J&J COVID-19 booster 6 or more months after receiving two doses of the Pfizer vaccine. Enrollment took place from Aug 12 to Oct 25, 2021, and follow-up lasted 4 months.

The median age of the 41 recipients of a J&J booster was 36 years, while it was 35 in the 27 Pfizer recipients. Of all participants, 82% were women, 78% were White, 10% were Asian, 6% were Black, 6% were Hispanic or Latino, and 4% were more than one race.

Antibodies fell dramatically 4 months after Pfizer booster

Both boosters were tied to improved humoral and cellular immune responses, including against SARS-CoV-2 variants of concern such as Omicron. A Pfizer booster was tied to a rapid rise in Omicron-neutralizing antibodies that peaked at a median titer of 1,018 in week 2, and then dropped 6.9-fold to 148 at 4 months. In contrast, after a J&J booster, Omicron-neutralizing antibodies rose, peaking at a median titer of 859 in week 4, and then fell only 2.1-fold to 403 by 4 months.

The findings, the researchers said, show that both COVID-19 vaccine strategies (same or different booster) increase Omicron-neutralizing antibody and T-cell responses in Pfizer vaccine recipients but that responses at 4 months were higher after the J&J booster than after the Pfizer version.

"A heterologous mix-and-match vaccine strategy was associated with durable antibody and T-cell responses against the SARS-CoV-2 Omicron variant," they wrote. "These data suggest potential immunologic benefits of mix-and-match heterologous COVID-19 vaccine regimens and emphasizes the importance of durability for COVID-19 vaccine boosting strategies."

The authors noted that previously reported rapid waning of SARS-CoV-2 antibody responses and clinical effectiveness after third and fourth doses of the Pfizer COVID-19 vaccine has led to recommendations for frequent mRNA vaccine boosting, "which may be challenging to sustain as a long-term policy in the developed world and difficult to implement in the developing world," they wrote. "Future studies could explore reduced booster doses as well as Omicron-containing boosters."

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»


Unrestricted financial support provided by

Bentson Foundation Unorthodox Philanthropy logo and text 'Leading Underwriter'3M logoGilead 
Grant support for ASP provided by


  Become an underwriter»